AIS is much less common than its squamous counterpart, cervical intraepithelial neoplasia (CIN) grade 3 (previously called severe dysplasia or carcinoma in situ). In a multistate surveillance study in the United States from 2008 to 2015, 470 AIS cases were documented compared with 6587 CIN 3 cases . The median age of patients with AIS was older ...

The new guidelines provide risk thresholds for clinical action (Table 1) and establish risk estimates for the development of cervical intraepithelial neoplasia grade 3 (CIN 3), adenocarcinoma in situ, or cancer (ie, CIN 3+) for different combinations of test results.

We identified AIS and CIN grade 3 (CIN3) cases through population-based surveillance, and analyzed data on HPV types and incidence trends overall, and among women screened for cervical cancer. From 2008 to 2015, 470 AIS and 6,587 CIN3 cases were identified. The median age of women with AIS was older than those with CIN3 (35 vs. 31 years; p < 0.01).

What is the “CIN” in CIN? • It stands for cervical intraepithelial neoplasia. • CIN may also be referred to as dysplasia, which means cellular overgrowth. • CIN 3 or III is a high-grade dysplasia — higher than the more moderate grade of II, which is more progressed than the mild form of I.

Adenocarcinoma in situ frequently coexists with squamous dysplasia. When concomitant AIS and CIN are diagnosed, management should proceed per the recommendations for AIS.

Surveillance of cervical intraepithelial neoplasia grade III (CIN III) and adenocarcinoma in situ (AIS) is important for determining the burden of a preventable disease, identifying effects of vaccination on future diagnoses, and developing targeted programs.

Nov 12, 2023 · High-grade squamous intraepithelial lesion (HSIL) is a squamous cell abnormality associated with human papillomavirus (HPV). It encompasses the previously used terms cervical intraepithelial neoplasia grades 2 and 3 (CIN 2 and CIN 3), moderate and severe dysplasia, and carcinoma in situ.

Methods: We observed 5-year risks of CIN 2+ for 3 follow-up management strategies after treatment (Pap-alone, human papillomavirus [HPV]-alone, and HPV/Pap cotesting) for 3,273 women aged 25 years and older who were treated for CIN 2, CIN 3, or adenocarcinoma in situ (AIS) between 2003 and 2010 at Kaiser Permanente Northern California.

Feb 15, 2006 · The Bethesda System should be used to communicate accurately the risk of cervical intraepithelial neoplasia (CIN) grades 2 and 3, adenocarcinoma in situ (AIS), or cancer (collectively, CIN...

Feb 1, 2020 · We identified AIS and CIN grade 3 (CIN3) cases through population-based surveillance, and analyzed data on HPV types and incidence trends overall, and among women screened for cervical cancer. From 2008 to 2015, 470 AIS and 6,587 CIN3 cases were identified.